Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KDS2010 in Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
NCT07027072Phase 2Recruiting
- Sponsor
- NeuroBiogen
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tisolagiline in Alzheimer's disease (AD), sponsored by NeuroBiogen. Started Aug 2025; status: recruiting.
02
Drugs
tisolagiline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07027072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027072.